<DOC>
	<DOCNO>NCT00527540</DOCNO>
	<brief_summary>Pegylation interferon prolongs medication half-life result Pegylated Interferon ( PEG-IFN ) new modality treatment chronic hepatitis C. We current clinical trial ass efficacy safety domestic PEG-IFN alpha-2a ( Pegaferon® ) patient chronic hepatitis C .</brief_summary>
	<brief_title>Effectiveness Side Effects Pegylated Interferon Alpha-2a ( Pegaferon® ) Plus Ribavirin Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>We enroll 50 patient study . The patient receive Pegaferon® 180 micgr per week plus ribavirin 10-15mg/kg per day . The patient visit every 4 week biochemistry lab test . They check quantitative HCV PCR third month initiation treatment assess early virologic response end study complete response rate six month treatment completion sustain response rate . The patient undetectable HCV RNA consider responder .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>HCV RNA : Positive Biopsy approve genotype 1 Age old 18 yr ongoing pregnancy breast feed Hx hemochromatosis Hx metabolic liver dis . Hx HCC Hx autoimmune hepatitis Hx alcoholic liver dis . Hx bleed esophageal varix ongoing systemic antiviral antineoplasmic treatment Hx treatment antidepressant medication therapeutic dos least 3 month pervious time Hx treatment tranquilizer therapeutic dos psychosis least 3 month pervious time Hx hospitalization psychiatric dis . Hx suicidal attempt Hx IBD Hx SLE Hx scleroderma Hx rheumatoid arthritis Hx ITP Hx autoimmune hemolytic anemia Hx severe psoriasis Hx chronic pulmonary dis . associate functional limitation Hx MI unstable angina Hx arrhythmia require ongoing treatment Hx functional class III IV Hx severe seizure dis . current anticonvulsant use Hx organ transplantation exist functional graft Hx severe retinopathy Hx Thalassemia Hx spherocytosis Hx cerebrovascular dis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>